Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2
Kerry J. Savage, Steven M. Horwitz, Ranjana H. Advani, Jacob Haaber Christensen, Eva Domingo‐Doménech, Giuseppe Rossi, Franck Morschhauser, Önder Alpdoğan, Cheolwon Suh, Kensei Tobinai, Andrei R. Shustov, Marek Trněný, Sam Yuen, Pier Luigi Zinzani, Lorenz Trümper, Tim Ilidge, Owen A. O’Connor, Barbara Pro, Harry Miao, Veronica Bunn, Keenan Fenton, Michelle A. Fanale, Markus Puhlmann, Swaminathan P. Iyer
Abstract
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have high relapse rates following standard therapy. Despite use of consolidative stem cell transplant (SCT) following frontline therapy, there remains no consensus on its utility. The double-blind randomized phase 3 ECHELON-2 study (#NCT01777152; clinicaltrials.gov) demonstrated improved progression-free survival (PFS) and overall survival with frontline brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP). Herein, we conducted an exploratory subgroups analysis of the impact of consolidative SCT on PFS in patients with previously untreated CD30+ PTCL (ALK- anaplastic large cell lymphoma [ALCL] and non-ALCL) who were in complete response (CR) after frontline treatment with A+CHP or cyclophosphamide, doxorubicin, vincristine, and prednisone. Median PFS follow-up was 47.57 months. The PFS hazard ratio was 0.36, equating to a 64% reduction in the risk of a PFS event in patients who underwent SCT. The median PFS in patients who underwent SCT was not reached, vs 55.66 months in patients who did not undergo SCT. PFS results favored the use of SCT in both ALK- ALCL and non-ALCL subgroups. These data support the consideration of consolidative SCT in patients with CD30+PTCL who achieve CR following treatment with A+CHP.